|9th October 2020||James Arthur Bristol||19,370||Open or private sale||$53.35||$1,033,451.48|
|9th October 2020||James Arthur Bristol||23,541||Exercise of derivative||$1.89||$44,492.49|
|9th October 2020||James Arthur Bristol||200||Open or private sale||$55.43||$11,086.00|
|9th October 2020||James Arthur Bristol||3,971||Open or private sale||$54.53||$216,531.09|
|2nd October 2020||Matthew L Sherman||2,632||Payment by withholding||$51.15||$134,618.11|
|1st October 2020||Michael Douglas Taylor||20,365||Exercise of derivative||$1.89||$38,489.85|
|1st October 2020||Michael Douglas Taylor||23,886||Open or private sale||$51.98||$1,241,596.67|
|1st October 2020||Michael Douglas Taylor||101,114||Open or private sale||$51.52||$5,208,887.71|
|1st October 2020||Michael Douglas Taylor||104,635||Exercise of derivative||$1.89||$197,760.15|
|14th September 2020||Thomas Patrick Kelly||3,000||Exercise of derivative||$1.89||$5,670.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Deciphera Pharmaceuticals, Inc. develops and manufactures kinase inhibitor treatments for cancer. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.